A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
ApexOnco Front Page
Recent articles
So who else could be interested in the oestrogen degrader?
Autogene cevumeran goes on hold in adjuvant bladder cancer.
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
ESO-T01 delivers its first four multiple myeloma case reports.
Multispecifics newly into the clinic include Car-Ts from Essen and Unicar.
PD-(L)1 x VEGF bispecifics prove a big draw.
The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.
